Page 375 - Binder2

• Mucosal tolerance mechanisms may reduce or
eliminate immunogenicity.
• AI-designed constructs lead to consistent protein
expression across batches.
• Shelf-stability and oral administration reduce the
need for procedural oversight.

So what remains for the physician?

A great deal—but the nature of their involvement changes:

From gatekeeper to guide.
Instead of authorizing access to scarce, complex drugs,
doctors become advisors on long-term immune modulation.

From drug administrator to immune coach.
Instead of managing infusions, they support patients on
therapeutic journeys that unfold gradually and sustainably.

From prescriber to partner.
In a system where patients can receive therapies by mail or
through community-based networks, physicians shift
toward collaborative care—co-developing strategies that
combine biologics with lifestyle, nutrition, and preventative
medicine.

This transformation isn’t about redundancy—it’s about
restoring trust and presence to the doctor-patient
relationship.

373